| islets (transplant scaffold carrier) |
β-cell line and human
islets |
alginate, gelatin, HA, matrigel |
layered 0/90 pattern |
n/a |
plunger-driven printing
(plotting) |
cells were mixed with hydrogels and post-cross-linked
with
different concentrations of CaCl2 for 15–30 min |
in vitro culture post bioprinting
during 14
days; abdominal and subcutaneous implantated in vivo during 7 days |
(498) |
| islets (transplant scaffold carrier) |
primary islets
(rat) |
alginate with (MC) |
square 9 × 9 mm, strand
distance 3 mm, 4 layers, 0/90 |
n/a |
pressure-assisted extrusion |
islets were mixed with alginate/MC, bioprinted, and cross-linked
with strontium chloride (SrCl2) |
an average
of 20% of the apoptic cells were observed in the
plotted contructs with small variations during 7 days of in vitro culture |
(500) |
| islets (transplant scaffold carrier) |
primary islets
(mouse), bone marrow derived endothelial progenitor
cells (EPC, mouse) or ECs (MS1, CRL-2279), blood isolated T cells (human) |
GelMA and alginate
blends |
single-layer 0/90 pattern |
n/a |
plunger extrusion-based |
core: islets with hydrogel
blends; shell: EPC with hydrogel
blend; constructs were printed and cross-linked with UV during and
after printing followed by CaCl2 (10 min) |
bioprinted constructs cultured for up to 3 days; cell -ree disks implanted subcutaneously
for 21 days |
(502) |
| pancreatic tumor model |
human tumor- derived cancer, stellate and ECs |
alginate-based |
layered |
n/a |
extrusion-based |
stromal
bioink 200 M cells/mL
(75% stellate cells + 25% HUVECs);
tumor bioink 150 to 300 M cells/mL
(75% tumor cells + 25% HUVECs); bioprinting;
cross-linking with CaCl2
|
in vitro and in vivo subcutaneous
implantation in immunodeficient mice |
(503) |
